vicky cardenas

26 References Related Articles Abstract Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. Methods We conducted the final analysis in the double-blind phase of our multinational, randomized, placebo-controlled trial, in which adults were assigned in a 1:1 ratio to receive single-dose Ad26.COV2.S (5×1010 viral particles) or placebo.

Jerald Sadoff, Mathieu Le Gars, Vicky Cardenas, Georgi Shukarev, Nathalie Vaissiere, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Gert Scheper, Jenny Hendriks, Javier Ruiz-Guinazu, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker doi: https://doi.org/10.1101/2021.08.25.21262569 Abstract Background: We evaluated the durability of SARS-CoV-2 antibody levels elicited by the single dose Janssen COVID-19 vaccine, Ad26.COV2.S, and the impact on antibody responses of...

Affiliations: The Aurum Institute, Parktown, South Africa, Vanderbilt University, Nashville, Tennessee, and University of the Witwatersrand, Johannesburg, South Africa (G.C.) The Aurum Institute, Parktown, South Africa (V.C., K.M., M.S., W.B., L.M., Z.W.) The Aurum Institute, Parktown, South Africa, and University of the Witwatersrand, Johannesburg, South Africa (V.C., S.C.) University of the Witwatersrand, Johannesburg, South Africa, and Amsterdam University Medical Centres, Amsterdam, the...